Published in Cancer Res on June 01, 2003
Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell (2014) 3.68
Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol (2010) 3.65
P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer (2005) 1.83
Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistance. J Cell Biochem (2006) 1.22
ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation. Clin Cancer Res (2013) 1.15
p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines. J Virol (2007) 1.09
Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells. Oncogene (2010) 0.99
Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression. J Clin Invest (2013) 0.99
Id4 dependent acetylation restores mutant-p53 transcriptional activity. Mol Cancer (2013) 0.91
Soluble guanylyl cyclase α1 and p53 cytoplasmic sequestration and down-regulation in prostate cancer. Mol Endocrinol (2011) 0.90
Intracellular CD24 disrupts the ARF-NPM interaction and enables mutational and viral oncogene-mediated p53 inactivation. Nat Commun (2015) 0.89
Enhanced radiosensitivity of androgen-resistant prostate cancer: AZD1152-mediated Aurora kinase B inhibition. Radiat Res (2011) 0.83
Ceramide Synthase 6 Is a Novel Target of Methotrexate Mediating Its Antiproliferative Effect in a p53-Dependent Manner. PLoS One (2016) 0.81
NeuroD1 regulation of migration accompanies the differential sensitivity of neuroendocrine carcinomas to TrkB inhibition. Oncogenesis (2013) 0.80
Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells. Int J Oncol (2016) 0.79
Combined Treatment of Androgen-Independent Prostate Cancer Cell Line DU145 with Chemotherapeutic Agents and Lithium Chloride: Effect on Growth Arrest and/or Apoptosis. Avicenna J Med Biotechnol (2012) 0.78
Mefloquine exerts anticancer activity in prostate cancer cells via ROS-mediated modulation of Akt, ERK, JNK and AMPK signaling. Oncol Lett (2013) 0.76
ID4 regulates transcriptional activity of wild type and mutant p53 via K373 acetylation. Oncotarget (2016) 0.75
Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness. Int J Mol Sci (2016) 0.75
The antioxidant function of the p53 tumor suppressor. Nat Med (2005) 7.57
Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science (2004) 5.88
An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science (2008) 4.89
Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies. Science (2010) 3.86
Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci U S A (2010) 3.81
Weak p53 permits senescence during cell cycle arrest. Cell Cycle (2010) 3.33
The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging (Albany NY) (2010) 3.27
Pseudo-DNA damage response in senescent cells. Cell Cycle (2009) 2.93
Identification of a novel stress-responsive gene Hi95 involved in regulation of cell viability. Oncogene (2002) 2.52
Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol (2006) 2.47
Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications. Cell Cycle (2009) 2.43
BMAL1-dependent circadian oscillation of nuclear CLOCK: posttranslational events induced by dimerization of transcriptional activators of the mammalian clock system. Genes Dev (2003) 2.37
Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in mice. Oncogene (2004) 2.34
Cellular quiescence caused by the Mdm2 inhibitor nutlin-3A. Cell Cycle (2009) 2.22
Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci U S A (2005) 2.14
Regulation of NF-kappaB by NSD1/FBXL11-dependent reversible lysine methylation of p65. Proc Natl Acad Sci U S A (2009) 2.10
Structural basis of TLR5-flagellin recognition and signaling. Science (2012) 2.10
Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT. Sci Transl Med (2011) 2.03
Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res (2006) 2.03
Implementation of virtual microscope slides in the annual pathobiology of cancer workshop laboratory. Hum Pathol (2003) 2.01
p53 is a suppressor of inflammatory response in mice. FASEB J (2005) 1.91
Circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the CLOCK/BMAL1 transactivation complex. Proc Natl Acad Sci U S A (2005) 1.91
Hypoxia suppresses conversion from proliferative arrest to cellular senescence. Proc Natl Acad Sci U S A (2012) 1.83
Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/- mice. Aging (Albany NY) (2012) 1.79
Pathologist workforce in the United States: I. Development of a predictive model to examine factors influencing supply. Arch Pathol Lab Med (2013) 1.78
Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. Oncotarget (2011) 1.73
Proteolytic cleavage of the p65-RelA subunit of NF-kappaB during poliovirus infection. J Biol Chem (2005) 1.71
p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs. Proc Natl Acad Sci U S A (2012) 1.71
An inducible model of abacterial prostatitis induces antigen specific inflammatory and proliferative changes in the murine prostate. Prostate (2011) 1.68
Small molecule screening reveals a transcription-independent pro-survival function of androgen receptor in castration-resistant prostate cancer. Cell Cycle (2009) 1.66
Maintenance of metabolic homeostasis by Sestrin2 and Sestrin3. Cell Metab (2012) 1.64
Repression of sestrin family genes contributes to oncogenic Ras-induced reactive oxygen species up-regulation and genetic instability. Cancer Res (2007) 1.63
Aberration in the expression of the retinoid receptor, RXRalpha, in prostate cancer. Cancer Biol Ther (2003) 1.58
A purine nucleotide biosynthesis enzyme guanosine monophosphate reductase is a suppressor of melanoma invasion. Cell Rep (2013) 1.58
A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation. Genes Dev (2006) 1.58
Trichostatin A (TSA) sensitizes the human prostatic cancer cell line DU145 to death receptor ligands treatment. Cancer Biol Ther (2005) 1.54
Sestrins inhibit mTORC1 kinase activation through the GATOR complex. Cell Rep (2014) 1.51
Keratinocyte growth factor (KGF) enhances postnatal T-cell development via enhancements in proliferation and function of thymic epithelial cells. Blood (2007) 1.51
Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. Genes Dev (2002) 1.49
Validation-based insertional mutagenesis identifies lysine demethylase FBXL11 as a negative regulator of NFkappaB. Proc Natl Acad Sci U S A (2009) 1.49
Apoptosis inhibitor as a suppressor of tumor progression: expression of Bcl-2 eliminates selective advantages for p53-deficient cells in the tumor. Cancer Biol Ther (2002) 1.48
MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer. Cancer Biol Ther (2008) 1.48
p53 pathway in renal cell carcinoma is repressed by a dominant mechanism. Cancer Res (2004) 1.47
New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53-/- mice by delaying carcinogenesis. Aging (Albany NY) (2012) 1.47
TRAIL-DISC formation is androgen-dependent in the human prostatic carcinoma cell line LNCaP. Cancer Biol Ther (2003) 1.47
Secreted transforming growth factor beta2 activates NF-kappaB, blocks apoptosis, and is essential for the survival of some tumor cells. Proc Natl Acad Sci U S A (2004) 1.45
Coauthorship in pathology, a comparison with physics and a survery-generated and member-preferred authorship guideline. MedGenMed (2004) 1.45
Bisindolylmaleimide IX Induces Reversible and Time-Dependent Tumor Necrosis Factor Receptor Family-Mediated Caspase Activation and Cell Death. Cancer Biol Ther (2003) 1.40
Commentary: Mentoring the mentor: executive coaching for clinical departmental executive officers. Acad Med (2010) 1.38
Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry. Prostate (2002) 1.32
Transcription of mammalian messenger RNAs by a nuclear RNA polymerase of mitochondrial origin. Nature (2005) 1.29
Core circadian protein CLOCK is a positive regulator of NF-κB-mediated transcription. Proc Natl Acad Sci U S A (2012) 1.28
Homeostatic functions of the p53 tumor suppressor: regulation of energy metabolism and antioxidant defense. Semin Cancer Biol (2008) 1.27
Pyrimidine biosynthesis links mitochondrial respiration to the p53 pathway. Proc Natl Acad Sci U S A (2010) 1.26
Inhibition of p53 response in tumor stroma improves efficacy of anticancer treatment by increasing antiangiogenic effects of chemotherapy and radiotherapy in mice. Cancer Res (2006) 1.23
Association of Mycoplasma hominis infection with prostate cancer. Oncotarget (2011) 1.19
Cancer resistance in the blind mole rat is mediated by concerted necrotic cell death mechanism. Proc Natl Acad Sci U S A (2012) 1.18
Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist. Proc Natl Acad Sci U S A (2013) 1.16
Mandatory second opinion in surgical pathology referral material: clinical consequences of major disagreements. Am J Surg Pathol (2008) 1.14
Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP. Oncogene (2005) 1.12
Tumor suppressor p53 and its homologue p73alpha affect cell migration. J Biol Chem (2003) 1.11
Different effect of proteasome inhibition on vesicular stomatitis virus and poliovirus replication. PLoS One (2008) 1.10
p53 inhibitor pifithrin alpha can suppress heat shock and glucocorticoid signaling pathways. J Biol Chem (2003) 1.10
Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis. Cancer Res (2006) 1.09
Identification of granulocyte colony-stimulating factor and interleukin-6 as candidate biomarkers of CBLB502 efficacy as a medical radiation countermeasure. J Pharmacol Exp Ther (2012) 1.09
Identification of new drug sensitivity genes using genetic suppressor elements: protein arginine N-methyltransferase mediates cell sensitivity to DNA-damaging agents. Cancer Res (2003) 1.09
Achieving successful deployment of Bt rice. Trends Plant Sci (2004) 1.06
Baby shampoo nasal irrigations for the symptomatic post-functional endoscopic sinus surgery patient. Am J Rhinol (2008) 1.06
Letters to the editor. Endocr Pract (2015) 1.06
Mechanisms of prostate cancer cell survival after inhibition of AR expression. J Cell Biochem (2009) 1.06
Chemotherapeutic agents up-regulate the cytomegalovirus promoter: implications for bioluminescence imaging of tumor response to therapy. Cancer Res (2007) 1.05
Death receptor-induced cell death in prostate cancer. J Cell Biochem (2004) 1.05
p53 determines multidrug sensitivity of childhood neuroblastoma. Cancer Res (2007) 1.05
Calcium/calmodulin-dependent kinase II plays an important role in prostate cancer cell survival. Cancer Biol Ther (2007) 1.04
Toll-like receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: implications for head-and-neck cancer radiotherapy. Int J Radiat Oncol Biol Phys (2011) 1.03
Runx2 regulates survivin expression in prostate cancer cells. Lab Invest (2009) 1.03
Prostate cancer cells tolerate a narrow range of androgen receptor expression and activity. Prostate (2007) 1.03
Prostatic intraepithelial neoplasia in mice with conditional disruption of the retinoid X receptor alpha allele in the prostate epithelium. Cancer Res (2002) 1.02
Impact of small fitness costs on pest adaptation to crop varieties with multiple toxins: a heuristic model. J Econ Entomol (2006) 1.02
Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells. Mol Cancer Res (2006) 1.02
Mouse prostate cancer cell lines established from primary and postcastration recurrent tumors. Horm Cancer (2010) 1.01
Slow disease progression in a C57BL/6 pten-deficient mouse model of prostate cancer. Am J Pathol (2011) 1.01
Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma. Cancer Res (2009) 1.01
A small molecule inhibitor of p53 stimulates amplification of hematopoietic stem cells but does not promote tumor development in mice. Cell Cycle (2010) 1.01
Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil. Oncogene (2002) 1.01
T-cell recognition of a prostate specific antigen is not sufficient to induce prostate tissue destruction. Prostate (2006) 1.00
Effects of Bacillus thuringiensis on non-target herbivore and natural enemy assemblages in tropical irrigated rice. Environ Biosafety Res (2004) 1.00
Ribonucleotide reductase and thymidylate synthase or exogenous deoxyribonucleosides reduce DNA damage and senescence caused by C-MYC depletion. Aging (Albany NY) (2012) 1.00
p53 Is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells. Endocrinology (2003) 1.00
Dominant negative form of signal-regulatory protein-alpha (SIRPalpha /SHPS-1) inhibits tumor necrosis factor-mediated apoptosis by activation of NF-kappa B. J Biol Chem (2002) 1.00